Corbus Pharmaceuticals Q3 net loss widens on higher expenses

By Reuters News


Overview

  • US biotech reported higher Q3 net loss, driven by increased operating expenses

  • Company began dosing in registrational TEMPO-1 study for oropharyngeal cancer

  • Reported positive topline Phase 1b data for CRB-913 in obesity


Outlook

  • Company expects cash on hand to fund operations into 2028

  • Corbus expects to report sutantatug envedotin plus Keytruda data in 1L OPSCC in Q1 2027

  • Company plans to engage with FDA on CRB-913 development and possible combination with GLP-1 therapy


Result Drivers

  • LICENSING MILESTONE - Q3 operating expenses rose mainly due to a $15 mln milestone payment under CSPC agreement for sutantatug envedotin

  • R&D SPENDING - Operating expenses rose year-over-year, reflecting higher research and development costs


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Net Loss

$37.75 mln

Q3 Loss Per Basic Share

$1.81

Q3 Operating Expenses

$38.82 mln


Analyst Coverage

  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy."

  • Wall Street's median 12-month price target for Corbus Pharmaceuticals Holdings, Inc. is $35.00, about 894.3% above its November 9 closing price of $3.52


Reuters Recommended Reads

  • Nov 9 - Compass Therapeutics Q3 net loss widens on higher R&D expenses

  • Nov 9 - Bicara Therapeutics Q3 net loss widens on higher R&D costs

  • Nov 10 - Ovid Therapeutics Q3 net loss widens as R&D spending rises


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk